Jeremy Meyer

Dr. Jeremy Meyer


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2015 in Journal of Hepatology
Verified
Journal Article
Open access
RMRaphael Meier
Raphael Meier
RMRedouan Mahou
Redouan Mahou
PMPhilippe Morel
Philippe Morel
JMJeremy Meyer
Jeremy Meyer
EMElisa Montanari
Elisa Montanari
LBLeo H. Bühler
Leo H. Bühler
Mesenchymal stem cell (MSC) transplantation was shown to be effective for the treatment of liver fibrosis, but the mechanisms of action are not yet fully understood. We transplanted encapsulated human MSCs in two mouse models of liver fibrosis to determine the mechanisms behind the protective effect. Human bone marrow-derived MSCs were microencapsulated in novel alginate-polyethylene glycol microspheres. In vitro, we analyzed the effect of MSC-conditioned medium on the activation of hepatic stellate cells and the viability, proliferation, cytokine secretion, and differentiation capacity of encapsulated MSCs. The level of fibrosis induced by bile duct ligation (BDL) or carbon tetrachloride (CCl4) was assessed after intraperitoneal transplantation of encapsulated MSCs, encapsulated human fibroblasts, and empty microspheres. MSC-conditioned medium inhibited hepatic stellate cell activation and release of MSC secreted anti-apoptotic (IL-6, IGFBP-2) and anti-inflammatory (IL-1Ra) cytokines. Viability, proliferation, and cytokine secretion of microencapsulated MSCs were similar to those of non-encapsulated MSCs. Within the microspheres, MSCs maintained their capacity to differentiate into adipocytes, chondrocytes, and osteocytes. 23% (5/22) of the MSC clones were able to produce anti-inflammatory IL-1Ra in vitro. Microencapsulated MSCs significantly delayed the development of BDL- and CCl4-induced liver fibrosis. Fibroblasts had an intermediate effect against CCl4-induced fibrosis. Mice transplanted with encapsulated MSCs showed lower mRNA levels of collagen type I, whereas levels of matrix metalloproteinase 9 were significantly higher. Human IL-1Ra was detected in the serum of 36% (4/11) of the mice transplanted with microencapsulated MSCs. MSC-derived soluble molecules are responsible for an anti-fibrotic effect in experimental liver fibrosis.

14 September 2019 in World Journal of Gastroenterology
Verified
Journal Article
Open access
JMJeremy Meyer
Jeremy Meyer
SNSurennaidoo Naiken
Surennaidoo Naiken
NCNiki Christou
Niki Christou
ELEmilie Liot
Emilie Liot
CTChristian Toso
Christian Toso
FRFrédéric Ris
Frédéric Ris
Reducing anastomotic leak in colorectal surgery: The old dogmas and the new challenges

1 November 2015 in Journal of Hepatology
Verified
Journal Article
Closed access
JMJeremy Meyer
Jeremy Meyer
ELEsma Lejmi
Esma Lejmi
PFPierre Fontana
Pierre Fontana
PMPhilippe Morel
Philippe Morel
CGCarmen Gonelle-Gispert
Carmen Gonelle-Gispert
LBLéo Bühler
Léo Bühler

1 July 2019 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
JMJeremy Meyer
Jeremy Meyer
LOLorenzo A. Orci
Lorenzo A. Orci
CCChristophe Combescure
Christophe Combescure
ABAlexandre Balaphas
Alexandre Balaphas
PMPhilippe Morel
Philippe Morel
FRFrédéric Ris
Frédéric Ris

8 February 2022 in Obesity
Verified
Journal Article
Open access
PDF file
IUIsabelle Uhe
Isabelle Uhe
JDJonathan Douissard
Jonathan Douissard
MPMichele Podetta
Michele Podetta
MCMickael Chevallay
Mickael Chevallay
CTChristian Toso
Christian Toso
JMJeremy Meyer
Jeremy Meyer
Objective: This study aimed to determine which bariatric procedure allows patients to obtain the best weight‐loss outcomes and a remission of type 2 diabetes.Methods: Databases were searched for randomized‐controlled trials comparing Roux‐en‐Y gastric bypass (RYGB) with sleeve gastrectomy (SG) or one‐anastomosis gastric bypass (OAGB). The mean difference (MD) or the relative risk was determined.Results: Twenty‐five randomized‐controlled trials were analyzed. Excess weight loss (EWL, percentage) was greater for RYGB patients at 3 years (MD: 11.93, p < 0.00001) and 5 years (MD: 13.11, p = 0.0004). Higher excess BMI loss (percentage) was found in RYGB at 1 year (MD: 11.66, p = 0.01). Total weight loss (percentage) was greater for RYGB patients after 3 months (MD: 2.41, p = 0.02), 6 months (MD: 3.83, p < 0.00001), 1 year (MD: 6.35, p < 0.00001), and 5 years (MD: 3.90, p = 0.005). No difference in terms of remission of type 2 diabetes was seen between RYGB and SG. EWL was significantly more important after OAGB than after RYGB after 1 year (MD: −10.82, p = 0.003).Conclusions: RYGB is more efficient than SG in the midterm. OAGB offers greater EWL than RYGB after 1 year, but further evidence is needed to confirm this result.

10 September 2020 in Lasers in Medical Science
Verified
Journal Article
Open access
PDF file
GLGregoire Longchamp
Gregoire Longchamp
ELEmilie Liot
Emilie Liot
JMJeremy Meyer
Jeremy Meyer
CTChristian Toso
Christian Toso
NBNicolas C. Buchs
Nicolas C. Buchs
FRFrederic Ris
Frederic Ris
Non-excisional laser therapies are emerging treatment for grades II and III hemorrhoidal disease (HD). However, so far, their efficiency is based on low-level evidence. Therefore, we aimed to systematically review the efficiency of non-excisional laser therapies for HD. MEDLINE/Pubmed, Web of science, Embase, and Cochrane were searched from database implementation until the April 17th, 2020. We included studies reporting at least one of surgical indicators of postoperative outcomes of laser therapies, encompassing laser hemorrhoidoplasty (LH) and hemorrhoidal laser procedure (HeLP). Fourteen studies describing LH and HeLP were included, representing 1570 patients. The main intraoperative complication was bleeding (0–1.9% of pooled patients for LH, 5.5–16.7% of pooled patients for HeLP). Postoperative complications occurred in up to 64% of patients after LH and 23.3% after HeLP. Resolution of symptoms ranged between 70 and 100% after LH and between 83.6 and 90% after HeLP. Moreover, four randomized controlled trials included in our review reported similar resolution after LH compared with hemorrhoidectomy or mucopexy and after HeLP compared with rubber band ligation. Recurrence rate was reported to range between 0 and 11.3% after LH and between 5 and 9.4% after HeLP. When compared with hemorrhoidectomy, LH showed conflicting results with one randomized controlled trial reporting similar recurrence rate, but another reporting decreased recurrences associated with hemorrhoidectomy. Laser therapies showed lower postoperative pain than hemorrhoidectomy or rubber band ligation. LH and HeLP are safe and effective techniques for the treatment of grades II and III HD.